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External beam radiation therapy with conventional fractionation to a total dose of 76–80 Gy represents themost adopted treatment
modality for prostate cancer. Dose escalation in this setting has been demonstrated to improve biochemical control with acceptable
toxicity using contemporary radiotherapy techniques. Hypofractionated radiotherapy and stereotactic body radiation therapy have
gained an increasing interest in recent years and they have the potential to become the standard of care even if long-term data
about their efficacy and safety are not well established. Strong radiobiological basis supports the use of high dose for fraction
in prostate cancer, due to the demonstrated exceptionally low values of 𝛼/𝛽. Clinical experiences with hypofractionated and
stereotactic radiotherapy (with an adequate biologically equivalent dose) demonstrated good tolerance, a PSA control comparable to
conventional fractionation, and the advantage of shorter time period of treatment. This paper reviews the radiobiological findings
that have led to the increasing use of hypofractionation in the management of prostate cancer and briefly analyzes the clinical
experience in this setting.
1. Introduction
Prostate cancer represents the most common male cancer
diagnosed inWestern countries after nonmelanomatous skin
cancer [1]. Since inmost cases the prostate cancer at diagnosis
is organ confined [2], radical prostatectomy and definitive
radiotherapy are the accepted standard for treating the vast
majority of prostate cancer cases. External beam radiation
therapy (EBRT) is the most diffused radiotherapy treatment
modality for treating patients with prostate cancer. A con-
formal delivery of treatment is ideally adopted in order to
spare asmuch as possible the amount of radiation received by
the surrounding normal tissues. Nowadays, conventionally
fractionated radiation therapy (CFRT, a single 1.8–2.0Gy
fraction lasting one hour per day, five days per week, for
about eight weeks) to a total dose of 76–80Gy represents
the most adopted treatment modality. Dose escalation in
this setting has been demonstrated to improve biochemical
control with acceptable toxicity using contemporary radio-
therapy techniques [3, 4]. CFRT schemes employing fraction
sizes of 1.8–2.0Gy are based upon the premise that tumors
typically are less responsive to fraction size than are late
responding normal tissues. The 𝛼/𝛽 ratio is a measure of
fractionation response,with low ratios (high𝛼/𝛽’s) associated
with late responding normal tissues. A low 𝛼/𝛽 is consistent
with a greater capacity for repair between fractions, with an
accompanying greater relative sparing with small fraction
sizes, than for tumors with their typically higher 𝛼/𝛽 ratios.
Under these conditions, an improved therapeutic ratio is
achieved with multiple small fractions for most types of
tumors. The 𝛼/𝛽 ratios are thought to be associated with
tumors; however, they are typically 8 or greater, whereas
for late responding normal tissues, values on the order of
3 or 4 or somewhat less are suggested from the analyses of
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numerous experimental and some clinical outcome studies.
There appear to be exceptions to such typical tumor response
to fractionation, however. Growth fraction (or effective cell
cycle time) has often been associated with fractionation
response, with slowly proliferating normal tissues (and some
slowly proliferating tumors) generally displaying stronger
than expected fraction size responses (low 𝛼/𝛽 ratios).
Hypofractionated radiotherapy (HFRT, a single 2.1–
3.5 Gy fraction, five days per week, for around four weeks)
has gained a considerable interest in recent years. Stereotactic
body radiation therapy (SBRT, a single 3.5–15.0Gy fraction,
five days per week, for about two weeks) has been recently
an object of increasing interest in the scientific community
due to the technical improvements that have made possible
the delivery of larger radiation fraction size; thus, it has the
potential to become the standard of care even if long-term
data about its efficacy and safety are not well established.
The aim of this paper is to review the radiobiological find-
ings that have led to the increasing use of hypofractionation
in the management of prostate cancer and briefly analyze the
clinical experience in this setting.
2. Radiobiological Basis of Hypofractionation
Considerable efforts are being devoted at the present time
to the improvement of radiotherapy and there is no doubt
that radiobiology has been very fruitful in the generation of
new ideas and in the identification of potentially exploitable
mechanisms. In the last years improvements in biological
knowledge have changed several aspects of radiobiology.
About 40 years ago, Thames and Withers largely studied the
influence of dose per fraction on response. In each study
and for each chosen dose per fraction the total radiation
dose (isoeffective dose) that produced some defined level of
damage to the normal tissue or to the tumor was determined
[5, 6]. The relationships between total dose and dose per
fraction for acutely responding tissues (i.e., high-turnover
tissues), late responding tissues (low or no turnover), and
tumours provided the basic information required to optimize
radiotherapy according to the dose per fraction and number
of fractions. Those pioneering studies showed that the iso-
effective total dose increased more rapidly with decreasing
dose per fraction for late effect than for acute effect, which
indicates a greater sensitivity of late responses to changes in
dose per fraction (Figure 1). The relationship between total
isoeffective dose and the dose per fraction in fractionated
radiotherapy can be described using the linear-quadratic
(LQ) cell survival model [LQ: ln 𝑆 = 𝛼𝑑 − 𝛽𝑑2] [7], that is,
the standard model for calculating isoeffects in the range of
conventional dose per fraction [8]. The steepness and curva-
ture of isoeffective lines are determined by 𝛼/𝛽 ratio. At the
present time it is strongly recommended that the LQ model
should always be used, with a correctly chosen 𝛼/𝛽 ratio, to
describe isoeffect dose relationships at least over the range of
doses per fraction between 1 and 5Gy [9–11]. The renewed
interest for hypofractionation has raised the problem of the
need to adapt LQ model to higher dose per fraction because
clinically the LQ model often underestimates tumor control
observed at radiosurgical doses [12]. However, recent papers
conclude that the available data do not support a need to
change the LQmodel at large dose per fraction, if 𝛼/𝛽 ratio is
selected appropriately [8, 13]. A possible explanation for the
difference in shape of dose-response relationships for early
and late responding tissues is the different distribution of the
cells through the cycle. The radiosensitivity of a population
of cells varies with the distribution of cells through the cycle,
with a greater radioresistance in the late phase 𝑆, in the
early 𝐺
1
, and in the quiescence phase 𝐺
0
[14]; likely many
late responding normal tissues are resistant owing to the
presence ofmany not-proliferating cells that are resting in𝐺
0
.
Early responding tissues that proliferate quickly can have a
part of cell in a radioresistant phase, but the redistribution
through all the phases of the cell cycle allows the cells to be in
more sensitive phases at the next fraction of radiation. At the
same time, the fast proliferation itself is a form of resistance
that increases the total number of cells to kill. Repopulation
occurring during a protracted, fractionated regimen helps to
spare normal tissues but is a potential danger for the control
of tumor. If the overall duration of fractionated radiotherapy
is increased, there will usually be greater repopulation of the
irradiated tissues, both in the tumor and in early-reacting
normal tissues. To counteract proliferation of tumor cells, an
extra dose is needed. The proliferation is relevant in mouse
skin about 2 weeks after the start of daily fractionation. The
longer cell cycle of human cells makes proliferation evident
after a longer period [15, 16]. As overall time increases, a
greater total dose had been required to control tumors that
show an accelerated repopulation of clonogenic tumor cells
at some point during fractionated radiotherapy. In head and
neck cancers, for treatment times longer than 4 weeks, the
effect of proliferation is equivalent to a loss of radiation dose
of about 0,48–0.6Gy/day [17, 18]. Prolonging overall time
within the normal radiotherapy range has a large sparing
effect on early reactions but little sparing effect on late
reactions, because the time at which extra dose is required to
counteract proliferation in late responding tissues in humans
is far beyond the overall time of any normal radiotherapy
regimen [19]. Thus, in acute responding tissues fraction size
and overall treatment time both determine the effect; instead
for late responding tissues fraction size is the dominant factor
in determining the radiation-induced effect. Acute and late
responding tissues are usually differentiated on the basis
of different alpha beta value, with high alpha beta (in the
range of 7–20Gy) for acute responding tissues and low alpha
beta, generally in the range of 0.5–6Gy, for late responding
tissues. It is common practice to apply to tumors the same
alpha beta of acute responding tissues of approximately 10Gy
[20, 21]. However there is evidence that some human tumor
types exhibit low alpha beta ratios and also breast and early
stage prostate cancer [22, 23], perhaps with alpha beta ratios
even lower than for late normal tissue reaction. This can be
due not only to different tumor characteristics but also to
cell variability into the tumor or uncontrolled confounding
factors, such as the presence of tumor hypoxia, repopulation,
or patient-to-patient variability.
As Withers wrote in 1985 “conventional is commonly
not universally correct, and so with dose fractionation in






















Figure 1: (Based on data from Withers and Thames [5, 6]) the
steepness and curvature of these lines are determined by the 𝛼/𝛽
ratio. The graph indicates a greater sensitivity of late responses to
changes in dose per fraction: using lower doses per fraction tends to
spare late reactions.
radiotherapy” [5]. The heterogeneity of cancer cells and
cancer types and the importance of overall treatment time
make altered fractionation more useful in selected cases.
3. Brief History of Radiobiological Hypothesis
Concerning 𝛼/𝛽 of Prostate Cancer
In radiobiology, the 𝛼/𝛽 ratio is used to estimate the effects
of radiation on various tissues and compare various dose
and fractionation schemes. The 𝛼/𝛽 ratio is estimated to be
>10Gy for early-responding tissues (e.g., skin, mucosa, and
most tumors) and 3–5Gy for late responding tissues (e.g.,
connective tissue, bladder/rectal mucosa, and muscles). In
1999 Brenner and Hall [10] promoted the hypothesis that
prostate tumors have exceptionally low values of 𝛼/𝛽. They
derived an 𝛼/𝛽 ratio of 1.5 Gy with a 95% confidence interval
of 0.8 to 2.2Gy, based on 367 patients from two treatment
centers. Their assumption stems from the documented result
that similar biochemical long-term control is achieved using
EBRT doses of about 70Gy in 1.8–2.0Gy fractions but
using 145Gy from permanent iodine-125 (I125) low-dose-
rate (LDR) irradiation. In 2001, Fowler et al. [24] updated
this analysis with 1020 patients from 11 centers and came
to the same result of 𝛼/𝛽 = 1.5Gy, with a narrower
confidence interval (1.25–1.75Gy). These ranges of values
were confirmed in a 2012 paper by Miralbell et al. [25] where
a retrospective study was performed on nearly 6,000 prostate
cancer patients from seven international institutional pri-
mary datasets treated with EBRT stratified by risk groups and
androgen deprivation status. A direct analysis of 5-year bio-
chemical relapse–free survival (bRFS) data with the linear-
quadratic (LQ) model was implemented to estimate the dose
fractionation sensitivity for this group of patients. Since the
initial hypothesis about a low 𝛼/𝛽 for prostate cancer derived
from brachytherapy data, a specific concern was expressed
toward the fact that neither Brenner and Hall [10] nor Fowler
et al. [24] assumed that repopulation in the tumors was
significant during low-dose-rate treatment with I125. Wang
et al. [26] and Kal and van Gellekom [27] took in account
the effect of tumor repopulation in their work to derive LQ
parameters for prostate cancer: all authors postulated that
this effect is not negligible for the accurate description of
the radiation therapy of prostate. This consideration caused
a 23% reduction of I125 dose from 145 to 112Gy and resulted
in an estimate of 𝛼/𝛽 = 3-4Gy instead of the previously
derived 1.5 Gy. Furthermore, the work of Brenner and Hall
[10] was questioned by King and Mayo [28] because of its
extremely low radiosensitivity (𝛼 = 0.036Gy−1). Such a low 𝛼
value leads to excessively low clonogenic cell numbers (in the
range of 10 to 100); the authors proposed that a solid tumor
would consist of a heterogeneous population of clonogens
with a spectrum of radiosensitivities. Recently, Pedicini et al.
[29] proposed a method to estimate intrinsic radiosensitivity
(𝛼), fractionation sensitivity (𝛼/𝛽), repopulation doubling
time, number of clonogens, and kick-off time for accelerated
repopulation of prostate cancer. They confirmed a low value
of𝛼/𝛽, 2.96Gy (95%CI 2.41–3.53Gy),with a correspondingly
high value of intrinsic radiosensitivity, 0.16Gy−1 (95% CI
0.14–0.18Gy−1), a realistic average number of clonogens, a
long kick-off time for accelerated repopulation, and a sur-
prisingly fast repopulation that suggests the involvement of
subpopulations of specifically tumorigenic stem cells during
continuing radiation therapy.
Finally it should be noted that all the above calculations
agreed on a small value of 𝛼/𝛽, providing an attracting
rationale to utilize HFRT in prostate cancer.
4. Clinical Experiences Involving HFRT
Zaorsky et al. [30] recently published an extensive review
concerning the history of HFRT. As stated by the authors, the
first initial retrospective experience reported about the use
of HFRT came from the UK. Over 200 patients were treated
at St. Thomas Hospital in London with hypofractionated
radiotherapy to a dose of 55Gy in 12 fractions and later to
doses of 36Gy in 6 fractions with low rectal and urological
complications [31, 32]. The trial included men with early
(T1-T2) and advanced (T3-T4) disease that were treated
by external beam radiotherapy. Depending on anatomy,
patients were treated with 3-field, 4-field, or a double rotation
technique from a cobalt-60 machine or linear accelerator.
One of the first phase III prospective randomized con-
trolled trials (RCTs) comparing CFRT and HFRT was pub-
lished by Lukka et al. [33] in 2005: in this trial a conventional
dose of 66Gy in 33 fractionswas compared to a hypofraction-
ated regimen of 52.5Gy in 20 fractions (dose per fraction =
2.625Gy) in more than 900 men with low and intermediate
risk prostate cancer. Surprisingly, the 5-year rate of failure
(both biochemical and clinical) was higher in the hypofrac-
tionated arm compared to the standard fractionation arm
(60% versus 53%, 𝑃 < 0.05). The worse outcome reported in
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the hypofractionated arm may be explained by the fact that,
for any 𝛼/𝛽 ratio >0.2, the biologically equivalent dose (BED)
of 52.5Gy in 20 fractions is expected to be lower than the BED
of 66Gy in 33 fractions. At a median followup of 5.7 years, no
difference in 5-year actuarial rate of late grade 3 or higher gas-
trointestinal or genitourinary toxicity was observed between
the two arms. Subsequently, Yeoh et al. [34, 35] reported
that opposite results regarding 217 patients with T1-2 prostate
carcinomas were randomized to either a CFRT or a HFRT
arm between 1996 and 2006. Treatments were predominantly
four-field box technique with customized blocks using 6–
23MV photons. Patient in the CFRT arm received a modest
dose of 64Gy in 32 fractions, while patients in the HFRT
arm received a total dose of 55Gy in 20 treatments. The
study population was represented by men with favorable-
risk prostate cancer. At a median followup of 90 months,
biochemical relapse-free survival (bRFS) was significantly
better with hypofractionation when Phoenix definition was
used (53% versus 34%,𝑃 < 0.5).The contrary results reported
by these two studies may be caused by a different number
of reasons: first, no specific assumptions about the 𝛼/𝛽 ratio
before the beginning of both trials. Second, the total dose
of the CFRT arms was 66Gy and 64Gy, respectively, which
is considerably lower than more contemporary conventional
doses of 78–80Gy utilized nowadays [3]. Finally, a different
definition of biochemical failure (BF) was utilized in the two
studies: while the Lukka et al. study [33] used mainly the
ASTRO definition [18] (3 consecutive PSA rises), Yeoh et al.’s
study [34, 35] used the ASTRO and Phoenix [36, 37] (nadir +
2 ng/mL) definitions.
After the publication of these initial RCTs comparing
CFRT and HFRT, modern prospective phase III superiority
trials were initiated based on the assumption that the 𝛼/𝛽
ratio for prostate cancer is 1.5 Gy. Dose escalation studies [38–
45] have been utilized to determine the standard of care in
determining the optimal CFRT schedule. Dearnaley et al. [38]
conducted a pilot for a phase III trial randomising 64Gy
versus 74Gy and reported 5-year biochemical control rates of
59% (standard dose) and 71% (escalated dose) (hazard ratio
0.64, 95% CI 0.38–1.10, 𝑃 = 0.10) with acceptable acute
and late toxicity [27]. The subsequent MRC RT01 trial [39]
randomised 862 men to the same fractionation regimens and
found that at 6 months after radiotherapy grade 2 or higher
toxicity was low [28]. However almost all of this toxicity
was seen in the group receiving 74Gy. In both arms the
radiotherapy was given in conjunction with androgen depri-
vation. This trial did also confirm an increase in biochemical
progression-free survival (60% with the lower dose and 71%
with the higher dose at 5-year followup, hazard ratio of 0.67
for clinical progression in the higher dose arm, CI 0.53–0.85,
𝑃 = 0.0007) and metastasis-free survival, in addition to a
reduction in need for salvage androgen suppression. Kupelian
et al. [40] pooled the data from nine institutions totaling over
4800 men. Despite the higher dose cohort (>72Gy) having
worse prognostic features, their 5-year biochemical disease-
free survival (bDFS) was significantly improved compared
to the cohort who received <72Gy [29]. Pollack et al. [41]
conducted a phase 3 trial comparing 70Gy to 78Gy without
androgen deprivation and found a significant improvement
in freedom from failure (including biochemical failure) in
the higher dose group (freedom from failure at 6 years: 64%
versus 70%, 𝑃 = 0.03 [30]. This included a reduction in the
incidence of distant metastasis in the subgroup of patients
with a PSA >10 ng/mL at 6 years of followup. However this
trial also confirmed an increase in rectal side effects in the
higher dose arm (grade 2 or higher toxicity: 26% versus
12%).This trial was conducted in the era before image-guided
radiotherapy (IGRT) and intensity-modulated radiotherapy
(IMRT) were standard and hence higher doses are likely to
be deliverable with less toxicity today. Peeters et al. [42] also
conducted a dose escalation trial randomizing 664men 68Gy
or 78Gy. The higher dose was associated with a 10% increase
in freedom from failure at 5 years (HR 0.74, 𝑃 = 0.02)
[31]. Zelefsky et al. [43] reported their experience of treating
over 2000 men between 1998 and 2004 in a nonrandomised
observational study. They found that increasing dose was
associated with better disease control for intermediate and
high-risk patients but did not find a statistically significant
association with the low-risk patients. Most patients in this
study received neoadjuvant hormone therapy.
Arcangeli et al. [44–46] compared HFRT versus CFRT in
patients with high-risk prostate cancer. The purpose of this
study was to compare the toxicity and efficacy of hypofrac-
tionated (62Gy/20 fractions/5 weeks, 4 fractions per week)
versus conventional fractionation radiotherapy (80Gy/40
fractions/8weeks). From January 2003 toDecember 2007, 168
patients were randomized to receive either hypofractionated
or conventional fractionated schedules of three-dimensional
conformal radiotherapy to the prostate and seminal vesicles.
All patients received a 9-month course of total androgen
deprivation. There was no reported difference in late toxicity
at five years between the two schedules. The 3-year freedom
from biochemical failure (FFBF) rates was 87% and 79% in
the hypofractionation and conventional fractionation groups,
respectively (𝑃 = 0.035). The authors concluded that, with
equivalent late toxicity between the two treatment groups, the
hypofractionated treatment resulted in better PSA control.
Kuban et al. [47] reported on the preliminary outcome
and toxicity of a phase III RCT which based the treatment
regimens on maintaining equivalent acute toxicities while
delivering a higher BED to the prostate. They randomized
102 men to receive CFRT (BED at 𝛼/𝛽 of 3 = 121) to a
dose of 75.6Gy in 42 fractions and 102 men to receive
HFRT (BED at 𝛼/𝛽 of 3 = 130) to a dose of 72Gy in 30
fractions. The 5-year Phoenix FFBF rates were 92% and
96% (not statistically significant), respectively, and no patient
had a clinical failure. Finally, Pollack et al. [48] recently
reported the results of the RCT they conducted. Between
June 2002 and May 2006, men with favorable- to high-risk
prostate cancer were randomly allocated to receive 76Gy in
38 fractions at 2.0Gy per fraction (CFRT) versus 70.2Gy
in 26 fractions at 2.7 Gy per fraction (HFRT). High-risk
patients received long-term androgen deprivation therapy
(ADT), and some intermediate-risk patients received short-
term ADT. There were no statistically significant differences
in late toxicity between the arms; however, in subgroup
analysis, patients with compromised urinary function before
enrollment had significantly worse urinary function after
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HFRT. No differences were observed in the two arms in terms
of BF or any other type of failure.The authors concluded that
even if HFRT did not result in a significant reduction in any
type of failure (biochemical and clinical) it is delivered in 2.5
fewer weeks.Menwith compromised urinary function before
treatment may not be ideal candidates for HFRT. Other RCTs
are currently ongoing. RTOG 0415 is a phase III RCT with
fractionation schedules similar to the regimen of phase I/II
trial by Kupelian et al. [49]. If the a/b ratio for prostate cancer
is closer to 10, the trial will demonstrate equivalence between
the fractionation regimens; if it is closer to 1.5, the HFRT
schedule should produce better rates of biochemical control.
While phase I and phase II portions of the CHHiP trial [50]
have estimated toxicity, the UK Medical Research Council
(MRC) phase III noninferiority study will include over 3000
patients in a 3-arm design to extrapolate the isoeffective dose
for complications and address whether HFRT is equivalent to
CFRT. The NCIC trial is a noninferiority trial that compares
78Gy in 2Gy fractions to 60Gy in 3Gy fractions. Its goal is
to demonstrate the safety and efficacy of HFRT and evaluate
it as a replacement for CFRT.
HDR brachytherapy has been historically used as a form
of hypofractionation for treating men affected by prostate
cancer. Using this technique, fractionation regimens of 48Gy
in 8 fractions or 54Gy in 9 fractions over 5 days have
demonstrated 70%PSA failure-free survival at 5 years, despite
the majority of these patients having high-risk disease [51].
Relapse-free survival at 3 years was 100% for the low-risk
patients included in this study. Five percent of patients had
grade 3 acute GU toxicity and 21% had grade 2 acute GU
toxicity. With regard to late toxicity, one patient had a grade
3 GI toxicity and 11% had grade 2 GU toxicity. Yoshioka et
al. updated their results in 2010 and had treated 112 men
with 54Gy in 9 fractions with HDR brachytherapy [52]. The
majority of these patients had high-risk disease and also
received androgen deprivation therapy (ADT). Overall 5-
year bRFS was 83%. This was achieved with 5% acute and
3% late grade 3 toxicity. Another cohort of 117 consecutive
patients was treated with escalating doses of 6 fractions HDR
from 36Gy to 43.5 Gy, delivered in 2 insertions one week
apart [53]. They report excellent 8-year bRFS of 94% for this
group of low- and intermediate-risk prostate cancer patients.
Four (3%) patients had grade 3 late urinary toxicity. Recently
Demanes et al. have described their experience of treating
298menwithmostly low- and low-intermediate-risk prostate
cancer [54]. Approximately half were treatedwith 36Gy in six
Gy fractions, and the others received 4 fractions of 9.5Gy over
2 days.The 8-year bRFSwas 97%.The grade 3GU toxicity was
5% overall, 24% grade 2, but this was scored per event, not
per patient, and hence the same patient with more than one
symptom would be scored multiple times. Late GI toxicity
was <1%. Mount Vernon Hospital has published outcomes
for a group of men, some with locally advanced prostate
cancer [55].Thiswas a dose escalation study so the first cohort
received 34Gy in 4 fractions over 3 days, the second cohort
36Gy, and the third cohort 31.5 Gy in 3 fractions over 2 days.
Only 25–31% patients had grade 1 or more toxicity at six
months and two patients had grade 3 toxicity.
5. Clinical Experiences Involving the Use of
SBRT for the Treatment of Prostate Cancer
SBRT in the management of prostate cancer constitutes a
relatively new option. So far, only phases I-II studies have
been published regarding its use, even if phase III trials are
currently ongoing [56]. The first prospective trial of SBRT
for prostate cancer was published by Madsen et al. [57],
who treated 40 patients with SBRT using a daily dose of
6.7 Gy to a total dose of 33.5 Gy (6.7Gy for 5 fractions).
The fractionation schedule was calculated to be equivalent to
78Gy in 2Gy fractions using an estimated 𝛼/𝛽 ratio of 1.5. At
the median followup of 41 months, there were no instances
of grade 3 gastrointestinal toxicity and only a single episode
of acute grade 3 genitourinary toxicity. There was no grade
3 or higher late toxicities. The PSA control rate was 90%
by the Phoenix definition [37]. Tang et al. [58, 59] treated
30 men in a phase I/II study. The eligible men had low-risk
prostate cancer and received 5 weekly doses of 7Gy to a total
dose of 35Gy. The SBRT technique consisted of intensity-
modulated radiotherapy (IMRT) with daily image guidance
using implanted gold fiducials. All patients had at least 6
months of followup. The treatments were well tolerated and
there was no grade 3 or 4 GI/GU toxicity. Although there
were initial grade 2 toxicities (13% GU and 7% GI), these
scores returned to or improved over baseline at 6 months.
The biochemical control after 18 months was 100%. Katz et
al. [60, 61] reported an experience of SBRT treatment given
to 304 patients with clinically localized prostate cancer. Most
received 5 fractions of 7.25Gy (total dose 36.25Gy). At a
median followup of 40 months (range of 9–58 months), 10
patients died of other causes and 9 were lost to followup.The
4-year actuarial freedom from biochemical failure is 98.5%,
93.0%, and 75%, for the low-, intermediate-, and high-risk
groups. Late toxicity included 4.2%RTOGgrade 2GI toxicity,
7.8% GU toxicity and 1.4% grade 3 GU toxicity. Freeman
and King [62] report their experience of treating 41 low-
risk prostate cancer patients with 35–36.25Gy in 5 fractions
[9]. None received adjuvant hormonal therapy. At a median
followup of 5 years the biochemical relapse-free survival was
93%.There has been no grade 3 or higher rectal toxicity. One
patient experienced grade 3GU toxicity after repeated instru-
mentation. 32% and 16% experienced grade 1-2 late GU and
GI toxicity, respectively. King et al. have also published their
experience of treating 67 men with low-risk prostate cancer
[63]. Patients were treated to a dose of 36.25Gy in 5 fractions
using CyberKnife and median followup was 2.7 years. The 4-
year bRFS was 94%. Importantly, they clearly showed that
alternate day treatment significantly reduces the chance of
GU and GI toxicity compared with daily hypofractionated
regimens and recommend that this should be the regimen of
choice. Towsend et al. [64] reported an analysis of the first
50 patients treated with CyberKnife radiotherapy for prostate
cancer. Most patients were affected with early to intermediate
stage prostate cancer. Two patients had metastatic disease
at presentation and were excluded. A total of 37 patients
received irradiation at a dose of 35 to 37.5 Gy in 5 fractions
of 7 to 7.5Gy per fraction. Assuming an alpha/beta ratio of
1.5 Gy, this process delivered an equivalent dose of 85 to 96Gy
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Table 1: SBRT efficacy in selected experiences.
Study Fractionation Stage Low risk High risk 5 yr bRFS
Townsend et al. 2011 [64]
48 patients
(37 monotherapy, 11 boost)
35–37.5 Gy in 5 fractions
(boost 17.6–25Gy in 2–5 fractions) 69% T1 Not reported
King et al. 2012 [63]
67 patients 36.25Gy in 5 fractions T1c or T2a/b 100% None 4-year bRFS 94%
Freeman and King 2011 [62]
41 patients 35–36.35Gy in 5 fractions Low risk None 93%
Katz et al. 2010 [61]
304 patients 35–36.25Gy in 5 fractions 92% T1c 70% 4%
1.3% failed so far
(17–30 month FU)
Madsen et al. 2007 [57]
40 patients 33.5 Gy in 5 fractions T1c or T2a 100% None 48 month bRFS 90%
Tang et al. 2008 [58]
124 patients 33.5 Gy in 5 fractions T1c or T2a 100% None 2 years: 90%
Abbreviations: bRFS: biochemical relapse-free survival.
in 2Gy fractions (EQD2). A subset of patients (𝑛 = 11)
received standard linear accelerator-based pelvic radiation
treatment either by intensity-modulated radiation therapy or
by tomotherapy and received a boost via the CyberKnife at
a dose of 17.6 to 25Gy in 2 to 5 fractions (EQD2 = 46.6–
72Gy). The mean pretreatment prostate specific antigen and
Gleason scores were 9.16 ng/mL and 7, respectively. Grade 2
acute genitourinary toxicity was reported by 10% of patients
(𝑛 = 5). Only 3 patients reported grade 3 acute genitourinary
toxicity. No gastrointestinal grade 2 or grade 3 toxicities were
reported. Table 1 summarizes the reported efficacy of SBRT
in the abovementioned papers.
So far the results of SBRT studies are very encour-
aging and stress the potential of SBRT in the manage-
ment of certain patients with prostate cancer. However all
the toxicity data gathered so far come from single-centers
experience and are often compared with older radiotherapy
technique that did not use state-of-the-art technology such
as IMRT or image-guided radiotherapy (IGRT). More solid
evidences will be available with the currently ongoing phase
III trials (NCT01584258—PACE Study, ISRCTN45905321—
Scandinavian HYPO).
6. Conclusions
Nowadays EBRT constitutes an established treatment modal-
ity for almost all prostate cancer patients. Determining the
optimal fractionation scheme has been one of the goals
of radiation oncologists. Most of the evidence provided
in the last decade by specialized literature about prostate
cancer radiosensitivity supports the hypothesis that prostate
tumor has an extremely low 𝛼/𝛽 ratio, thus encouraging
the adoption of hypofractionated schedules in this setting.
There is a growing body of compelling evidence supporting
the safety and efficacy of abbreviated radiotherapy schedules
for prostate cancer. So far results of RCTs comparing HFRT
and CFRT have been puzzling due to a different number of
factors (different doses, radiation techniques, and contouring
policies). Results obtained from short-term SBRT have been
promising so far, but longer followup and phase III trials are
warranted.
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